Selpercatinib(LOXO-292) CAS 2152628-33-4 best service fast delivery large stock high quality
1 Inquiries
2152628-33-4
Pharmaceutical Grade
99.89%
Million
25kg/Cardboard Drum
Yes
2039-12-30
Avanafil,Tirzepatide,Semaglutide,Pregabalin,Nootropics,MT2
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceSelpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers. Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc.|Selpercatinib is a Kinase Inhibitor. The mechanism of action of selpercatinib is as a Rearranged during Transfection (RET) Inhibitor, and Cytochrome P450 2C8 Inhibitor, and Cytochrome P450 3A Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor, and Multidrug and Toxin Extrusion Transporter 1 Inhibitor.|Selpercatinib is an orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, selpercatinib selectively binds to and targets wild-type RET as well as various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. In addition, selpercatinib targets, binds to and inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and 3 (VEGFR3), and fibroblast growth factor receptor 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.
Class: receptor tyrosine kinase; Treatment: RET-altered lung/thyroid cancers; Other name: ARRY-192, LOXO-292; Oral bioavailability = 73%; Elimination half-life = 32 h; Protein binding = 97%Basic Info-
Product Name:
Selpercatinib
Other Name:CPD2206;LOX-292;LOXO-292; LOXO292;LOXO 292;LOXO-292,Selpercatinib;Selpercatinib(LOXO-292);6-?(2-?Hydroxy-?2-?methylpropoxy)?-?4-?[6-?[6-?[(6-?methoxy-?3-?pyridinyl)?methyl]?-?3,?6-?diazabicyclo[3.1.1]?hept-?3-?yl]?-?3-?pyridinyl]?pyrazolo[1,?5-?a]?pyridine-?3-?carbonitrile;Pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]-;LOXO-292 USP/EP/BP
CAS No.:2152628-33-4
Molecular Formula:C29H31N7O3
InChIKeys:XIIOFHFUYBLOLW-UHFFFAOYSA-N
Molecular Weight:525.6
Exact Mass:525.24883788
EC Number:207-854-9
UNII:CEGM9YBNGD
NCI Thesaurus Code:C134987
Color/Form:White to off-white
ATC Code:L01EX22
Categories:
Characteristics-
Density:
1.36±0.1 g/cm3(Predicted)
Water Solubility:<1 mg/mL
PKA:14.00±0.29(Predicted)
Critical Temperature & Pressure:Store at -20°C
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Avanafil,Tirzepatide,Semaglutide,Pregabalin,Nootropics,MT2
-
Location:
Room 1-2208, Lianhecaifu Square, No2177, Tianchen Road, Gaoxin District, Jinan City, Shandong Province, China
-
Payment Terms:
L/C,100% TT in advance
-
Average lead Time:
3 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2012
Company Certificates-
business license
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted 
Pakistan
Selpercatinib
500 MG Jun 24, 2025 Post an enquiry for this product
More from this Seller
-
-
![Levamisole high quality raw powder good feedback]( "Levamisole high quality raw powder good feedback")
-
Levamisole high quality raw powder good feedback
Pharmaceutical Grade / 99%
$1/UNIT FOB
-
-
-
![Irofulven cas 920014-72-8]( "Irofulven cas 920014-72-8")
-
Irofulven cas 920014-72-8
Pharmaceutical Grade / 99.56%
$1.8/G FOB
-
-
-
![Human Growth Hormone]( "Human Growth Hormone")
-
Human Growth Hormone
Pharmaceutical Grade / 99%
-
-
-
![Lemborexant high quality factory supply]( "Lemborexant high quality factory supply")
-
Lemborexant high quality factory supply
Pharmaceutical Grade / 99%
$1/UNIT FOB
-
-
-
![Mannitol, CAS87-78-5, factory supply]( "Mannitol, CAS87-78-5, factory supply")
-
Mannitol, CAS87-78-5, factory supply
Pharmaceutical Grade / 99.77%
$1.2/KG FOB
-
-
-
![Pregabalin CAS 148553-50-8 99% High Purity White Powder Hot Sale Pharmaceutical Best Service]( "Pregabalin CAS 148553-50-8 99% High Purity White Powder Hot Sale Pharmaceutical Best Service")
-
Pregabalin CAS 148553-50-8 99% High Purity White Powder Hot Sale Pharmaceutical Best Service
Pharmaceutical Grade / 99.56%
$2.5/G FOB
-
